Literature DB >> 12234616

Effects of nitrosopropofol on mitochondrial energy-converting system.

Roberto Stevanato1, Federico Momo, Michela Marian, Maria Pia Rigobello, Alberto Bindoli, Marcantonio Bragadin, Ezio Vincenti, Guido Scutari.   

Abstract

Nitrosopropofol (NOPR) is a relatively stable compound obtained from the reaction between the general anesthetic 2,6 diisopropylphenol (propofol) and nitrosoglutathione (GSNO) and bearing a more acidic phenol group than propofol. It interfered with mitochondrial energetic metabolism in a concentration-dependent manner. Concentrations as high as 100 or 200 microM disrupted both oxidative phosphorylation and electron transport. Low concentrations of NOPR (50 microM) markedly slowed down the electron transport rate which was insensitive both to ADP and uncoupler stimulation and spontaneously gradually stopped. Consequently, both the transmembrane potential production and the ATP synthesis system were affected. In the presence of 10 or 20 microM NOPR, mitochondria respired but showed a worsening of the respiratory control and produced a transmembrane potential useful to respond to a phosphorylation pulse, but were not able to restore it. These results were consistent with ATP synthesis and swelling experiments. NOPR was effective at concentrations lower than those required by the combination of propofol and GSNO, suggesting that mitochondria might be able to catalyze the reaction between GSNO and propofol and that the resulting metabolite was more active on mitochondrial membrane structure than the parent compounds. Although the details of the process are yet unknown, the mechanism presented may be of potential relevance to rationalize the pathophysiological effects of propofol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234616     DOI: 10.1016/s0006-2952(02)01253-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Effect of remifentanil on mitochondrial oxygen consumption of cultured human hepatocytes.

Authors:  Siamak Djafarzadeh; Madhusudanarao Vuda; Jukka Takala; Stephan M Jakob
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

2.  Treating critical illness: the importance of first doing no harm.

Authors:  Mervyn Singer; Paul Glynne
Journal:  PLoS Med       Date:  2005-06-28       Impact factor: 11.069

Review 3.  Critical illness and flat batteries.

Authors:  Mervyn Singer
Journal:  Crit Care       Date:  2017-12-28       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.